

DR JOHN FRANCIS STEWART

MEDICAL ONCOLOGIST

MBBS FRACP

QUALIFICATIONS

**Undergraduate
High Distinctions
Distinction**

Credits

University of Sydney 1968

Biology I
Physics I
Biology II
Chemistry
Introductory Medical Science
Biochemistry I & II
Physiology I & II
Histology & Embryology I
Pathology
Pharmacology
Bacteriology
Psychiatry
Preventative & Social Medicine
Medicine
Surgery
Obstetrics

E.C.F.M.G. (1973)

Graduated with Class II Honours (1974)

Represented Sydney University Rugby Union (1969)

Assistant Treasurer, Sydney University Medical Society (1970)

Unallocated Term Director, Sydney University Medical Society (1973)

ACCREDITATIONS

POSTGRADUATE

**Fellowship of Royal Australian College of Training Physicians (F.R.A.C.P) Part 1,
Examination passed (1977)**

**Advanced Trainee of Royal Australian College of Physicians in Medical
Oncology(1978-1980)**

Fellow, Royal Australian College of Physicians (1981)

SUB-SPECIALTIES

Medical Oncologist

CURRENT POSITIONS

Senior Staff Specialist (Current)
Newcastle Mater Misericordiae Hospital

Visiting Medical Oncologist (Current)
Royal Newcastle Hospital

Consultant Oncologist (Current)
Toronto Private Hospital

Consultant Oncologist (Current)
Warners Bay Private Hospital

Consultant Senior Lecturer (January 1997-Current)
Faculty of Medicine and Health Sciences
University of Newcastle

VMO (Current)
Lingard Private Hospital

MEMBERSHIP OF PROFESSIONAL SOCIETIES

Member – *Clinical Oncological Society of Australia.*

Member – *American Society of Clinical Oncology.*

Member – *Medical Oncology Group of Australia.*

Member – *European Society of Medical Oncology.*

PROFESSIONAL EXPERIENCE

HOSPITAL APPOINTMENTS

Junior Resident (1974)
Royal Prince Alfred Hospital Professional Unit

Medical Resident (1975)
Royal Prince Alfred Hospital

Senior Medical Resident (1976)
Royal Prince Alfred Hospital

Medical Registrar (1977)
Royal Prince Alfred Hospital

Registrar in Medical Oncology (1978)
Ludwig Institute for Cancer Research - Royal Prince Alfred Hospital

Hon. Medical Registrar (1979)
Royal Marsden Hospital, Sutton, Surrey, United Kingdom

Medical Registrar (1979)
ICRF Medical Oncology Unit, St Bartholomew's Hospital, London

Clinical Research Fellow (1979)

ICRF

Senior Registrar (1982)

Breast Unit, Department of Medical Oncology, Guy's Hospital, London, United Kingdom

Senior Lecturer (Temp) (1982-1983)

Faculty of Medicine University of Newcastle, NSW 2307

BIOGRAPHY

LOCATION

New South Wales

ADDITIONAL INFO

PUBLICATIONS

- (1) Stewart, J.F. Hepatoma. Royal Prince Alfred Hospital Clinical News Bulletin, 1978.
- (2) Stewart, J.F. M.H.N. Tattersall, R.L. Woods and R.M. Fox. Unknown primary adenocarcinoma: incidence of over-investigations and natural History. Brit. Med. J. 1:1530-1533, 1979.
- (3) Stewart, J.F., R.L. Woods, R.M. Fox, and M.H.N. Tattersall: Cis dichlorodiammine platinum (II) in advanced ovarian carcinoma. Med. J. Aust. 1(12):548-550, 1979.
- (4) Woods, R.L., J.F. Stewart, R.M. Fox, and M.H.N. Tattersall: Combination chemotherapy with Vincristine, Bleomycin and Methotrexate for advanced Head and neck cancer. Cancer Treat. Reps. 63 (11-12):1997-1999, 1979.
- (5) Woods, R.L., J.F. Stewart: Metastatic basal cell carcinoma: report of a case responding to chemotherapy. Postgraduate Medical Journal (April 1980) 56, 272-273.

- (6) Stewart, J.F., R.J.B. King, S.A. Sexton, R.R. Millis, R.D., Rubens and J.L. Hayward: Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur. J. Cancer, 67(4): 449-453, 1981
- (7) Stewart, J.F.: Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. International Synopses. December, 1981, p13.
- (8) Stewart, J.F. et al: Trial of Tamoxifen at a dose of 40 mg daily after disease progression during Tamoxifen therapy at a dose of 20 mg daily. Cancer Treat. Rep. 66:1445-1446, 1982.
- (9) Rubens, R.D., R. Steiner, J.F. Stewart, and R.K. Knight: Adriamycin with and without Vincristine in the treatment of advanced breast cancer. In: Current Chemotherapy and Immunotherapy. Vol 11. Proceedings of the 12th International Congress of Chemotherapy, Florence 19-24 July, 1981. Eds. P. Periti and G. Grassi. pp487-488.
- (10) Stewart, J.F. et al: Contribution of Prednisolone to primary endocrine therapy in advanced breast cancer. Eur. J. Cancer and Clin. Oncol. 18, no. 12:1307-1314, 1982.
- (11) Stewart, J.F. et al: Oestrogen receptors, clinical features and prognosis in Stage III breast cancer. Eur. J. Cancer and Clin. Oncol. 18, No. 12:1315-1320, 1982.
- (12) Stewart, J.F. et al: Oestrogen receptors status of advanced breast cancer immediately before chemotherapy does not predict for response. Cancer Chemother. Pharmacol. 9:124-125, 1982.
- (13) Stewart, J. F. et al: Oestrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis. Breast Cancer Research and Treatments, 243-250, 1982.
- (14) Stewart, J.F. et al: Serum Sialyl transferase levels in patients with metastatic breast cancer treated by chemotherapy. Brit. J. Cancer, 46:208, 1982.
- (15) King, R.J.B., Stewart, J.F., et al: Quantitative estimation of estradiol and progesterone receptor contents of primary and metastatic human breast tumours in relation to their response to endocrine treatment. Breast Cancer Research and Treatment 2,339-346, 1982.

- (16) Stewart, J.F., et al: Post-operative serum sialyltransferase levels and prognosis in operable breast cancer. Breast Cancer Research and Treatment: 3, 225-230, 1983.
- (17) Stewart, J.F.: Oestrogen receptors, Med. J. Aust. 2,365-366, 1983.
- (18) Steiner, R., J.F. Stewart et al: Results of endocrine therapy do not predict response to chemotherapy in advanced breast cancer. Eur. J. Cancer. Clin. Oncol. 19, pp1559-1563, 1983.
- (19) Stewart. J.F. et al: Steroid receptors, patient characteristics and prognosis in operable (Stage I & II) breast cancer. Eur. J. Cancer and Clin Oncol. 19, pp1381-1387, 1983.
- (20) Steiner, R., J.F. Stewart et al: A randomised trial of Adriamycin vs Adriamycin & Vincristine chemotherapy in advanced breast cancer. Eur. J. Cancer Clin. Oncol. 19. pp1553-1557, 1983.
- (21) Stewart, J.F., and R.D. Rubens: General prognostic factors in breast cancer. In breast disease: Recent advances in diagnosis and treatment. Edited by G. Bonnadonna. J. Wiley Publishers. pp141.168.
- (22) Amiel, S. J.F. Stewart et al: Adriamycin and Mitomycin C chemotherapy in advanced breast cancer. Eur. J. Cancer Clin. Oncol. 20, pp631-634.
- (23) Smart, Y.C., Rogers, K.M., Brien, J.H., Stewart JF, et al: Factor affecting MSA levels in normal women and women with breast cancer. Aust N.Z. J. Surg. 59:805-809, 1989.
- (24) Cooper SG, Denham JW, Hamilton CS, Joseph DJ, Stewart J.F. Ackland SP: The price of a false negative mammogram and an enthusiastic lay press. (letter) Med. J. Aust. 150-664, 1989.
- (25) Smart, Y.C., Stewart. J.F. Bartlett, et al: Mammary serum antigen (MSA) in advanced breast cancer. Breast Cancer Research & Treatment 16:23-28, 1990.
- (26) Joseph, D.J., Hamilton, C.S., Denham, J.W. Ackland, S.P., Stewart, J.F: Whither screening mammography Australia? Establishing a satisfactory basis for funding. Med. Journal of Australia, Vol. 152.545-546, May 1990.
- (27) Bonaventura, A., Stewart. J.F: Complete response of a transitional cell carcinoma of the renal pelvis to 5-Fluorouracil/Leucovorin chemotherapy.

A case report. Aus & NZ. Med. Journal (in press).

- (28) Cooper SG, Bonaventura A, Ackland SP, Stewart JF, Hamilton CS, Denham JW: Pelvic radiotherapy with concurrent 5-fluorouracil (5-FU) modulated by leucovorin for rectal cancer: a phase II study. Clin. Oncol. 5:169-173, 1993.
- (29) Denham JW, Hamilton CS, Christie D, O'Brien M, Bonaventura A, Stewart JF, Ackland SP, Lamb DS, Spry NA, Dady P, Atkinson CH, Wynne C, Joseph D: Simultaneous adjuvant radiation therapy and chemotherapy in high risk breast cancer-toxicity and dose modification: a Trans-Tasman Radiation Oncology Group multi-institution study. Int. J. Radiation Oncology Biol. Phys. 31:305-313, 1995.
- (30) Stewart JF, Bonaventura A, Ackland SP, Kilmurray J, Hamilton C, O'Brien P, Denham J: Toxicity of synchronous chemotherapy and radiotherapy for rectal cancer. Proc. Am. Soc. Clin Oncol. 14:224, 1995.
- (31) Leong DCS, Kinlay S, Ackland S, Bonaventura, Stewart JF: Low risk febrile neutropenia in a Medical Oncology Unit. Aust. & N.Z. J. Med. (submitted 15/7/96).
- (32) Liu Jun-Ping, Yajima Yukiko, Li He, Ackland SP, Akita Y, Stewart JF, Kawashima: Molecular interactions between dynamin and G-protein $\beta \gamma$ subunits in neuroendocrine cells. Mol.Cell.End. 132:61-71,1997.
- (33) Byrne MJ, Gebiski V, Forbes J, Tattersall MHN, Simes RJ, Coates AS, Dewar J, Lunn M, Flower C, Gill PC, Stewart J for the Australian-New Zealand Breast Cancer Trials Group: Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: A phase III randomised trial. J. Clin Oncol. 15: 3141-3148, 1997.
- (34) Newell S, Girgis A, Sanson-Fischer, RW, Stewart J: Are touchscreen computer surveys acceptable to medical oncology patients? J. Psychosocial Oncol. 15(2): 37-46, 1997
- (35) Sakoff JA, Stewart JF and Ackland SP Cytotoxicity of the new thymidylate synthase inhibitor AG337. Proc. 9th Lorne Cancer Conference, 1997.
- (36) Sakoff JA, Stewart JF and Ackland SP: Time-dependent apoptotic death induced by AG337. Proc. Am. Ass. Cancer Res. 38:47, 1997.

- (37) Garg M, Sakoff J, Johnson c, Stewart J and Ackland S: Within and between days variation in plasma levels (cp) of dihydrofluorouracil (FUH2) and 5-fluorouracil (5FU) during continuous infusion (CI). Proc. Am. Ass Cancer Res. 39:187, 1998.
- (38) Sakoff JA, Ackland SP and Stewart JF: AG337 induces cell cycle arrest, apoptosis and mitochondrial perturbations. Proc. Am. Ass. Cancer Res. 39:608, 1998.
- (39) Sakoff JA, Ackland SP and Stewart JF: thymitaq induces a reduction in the mitochondrial membrane potential cell cycle perturbations and apoptosis. Proc. 10th Lorne Cancer Conference, 1998.
- (40) Theriault RL, Lipton A, Hortobagyi GN, Gluick S. Stewart JF. et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J. Clin. Oncol. Vol. 17, No. 3 (March): 846-854, 1999
- (41) Ackland SP, Stewart JF: Locally advanced and metastatic breast cancer. In: Cancer Facts: A Concise Oncology Text. JF Bishop (ed), Ilarwood Academic Publishers (Amsterdam, NL) pp151-157, 1998.

ABSTRACTS

- (1) Rubens, R.D., JF Stewart, R.J.B. King, MJ Minton, G.E. Sparrow and R. K. Knight: Primary endocrine therapy plus prednisolone in advanced breast cancer. Proc. ASCO No. C-404, 1981.
- (2) Stewart, J.F., R.J.B. King and R.D. Rubens: Oestrogen receptors and prognosis in primary locally advanced breast cancer. Proc. AACR No. 588, 1981.
- (3) Stewart J.F. R.J.B. King and R.D. Rubens: Oestrogen receptor status of breast cancer immediately before chemotherapy and response to treatment. BACR, Abstract 3:8, Brit. J. Cancer, August, 1981.

- (4) Rubens, R.D., R. Steiner, J.F. Stewart, and R.K. Knight: Adriamycin & Vincristine in the treatment of advanced breast cancer. Proc. 12th International Congress of Chemotherapy. Abst. 389, 1981.

- (5) Stewart J.F., R. King, R. Steiner and R.D. Rubens: Oestrogen and progesterone receptors and response to endocrine therapy in advanced breast cancer. Proc. UICC Conference of Clinical Oncology, 1981.

- (6) Steiner, R., R.D. Rubens, and J.F. Stewart: Adriamycin & Vincristine in the treatment of advanced breast cancer. Proc. UTCC Conference of Clinical Oncology, 1981.

- (7) Stewart. J.F. et al: The value of repeating steroid receptor analyses in the endocrine treatment of breast cancer. Proc. Amer. Assoc. Clinical Oncology. Vol. 1:74, 1982.

- (8) Steiner, R., J.F. Stewart and R.D. Rubens: Does response to endocrine therapy predict response to chemotherapy? Proc. Amer. Assoc. Cancer Research. Vol 23:143, 1982

- (9) Blackburn, A.M., D. Wang, R.D. Bulbrook, J.F. Stewart et al: Hormone profiles in patients with breast cancer on primary treatment & prednisolone. Proceedings 13th International Cancer Congress.

- (10) J.F. Stewart, R. Burton, C. Smart: Elevated serum levels of 3E I breast cancer antigen in patients with advanced breast cancer. 4th EORTC Breast Cancer Working Conference 1987, Abstract No. D3.6.

- (11) A. Bonaventura, S. Ackland, J. Stewart: Intermediate dose leucovorin and 5-fluorouracil (LV/5FU) in metastatic colorectal cancer local experience. Proc. COSA 1989.

- (12) J.F. Stewart, R. Burton, C. Smart, Elevated levels of a mammary serum antigen (MSA) in patients with advanced breast cancer. Proc. ASCO Vol. 8:120, 1989

- (13) A. Bonaventura, J.Stewart, S. Ackland, C. Hamilton, D. Joseph, J. Denham: Synchronous adjuvant radiotherapy (RT) and chemotherapy (CT) for early breast cancer. Proc. ASCO Vol. 9:103, 1990

- (14) A. Bonaventura, S. Ackland, J. F. Stewart: Intermediate dose leucovorin, and 5-fluorouracil (LV/5FU) in metastatic colorectal cancer. Proc. ASCO Vol. 9:429, 1990

- (15) Ackland SP, Hamilton CS, Stewart JF, Bonaventura A, Joseph D, Denham JW, synchronous leucovorin, 5-F and radiation therapy (RT) for colorectal tumours. Proc. American Society For Clinical Oncology 10:466, March 1991

- (16) Ackland SP, Mearrick P, Stewart JF, Von Jenner N, Pacciarini MA: Pharmacokinetics of epirubicin during 120-hour infusion. Presented at 18th Annual Scientific Meeting of Clinical Oncological Society of Australia, December 1991.

- (17) Bonaventura A, Ackland SP, Stewart JF, Hamilton CS, Joseph D, Denham JW, Santhanam A: Synchronous leucovorin, 5-FU and radiotherapy for colorectal tumours. Presented at Clinical Oncological Society of Australia, December 1991.

- (18) Bonaventura A, Stewart JF, Ackland S et al: Synchronous adjuvant radiotherapy (RT) and chemotherapy for early breast cancer. Proc 5th EORTC. Breast Cancer Working Conference. pA288, Leuven, Belgium, 1991.

- (19) Casinader A. Leaver B, Stewart JF: Audit of wastage incurred in the course of cytotoxic drug utilisation at the Newcastle Mater Misericordiae Hospital.

Presented at Clinical Oncological Society of Australia, December 1991

- (20) Abell F, Bonaventura A, Stewart JF, Ackland SP, Clarke V: Adjuvant intermediate dose leucovorin (LV) a 5-fluorouracil (5-FU) in colon cancer. Presented at 19th Annual Scientific Meeting of Clinical Oncological Society of Australia, December 1992

- (21) Stewart JF: Review of Treatment of Testicular Cancer at the Newcastle Mater Misericordiae Hospital. Presented at the Annual Scientific Meeting of the Westlakes Medical Committee Roche Raquet Resort, 5th, 6th June 1994.

- (22) Stewart JF: Chemotherapy in Local Control of Breast Cancer, Presented at the Annual Meeting of the NSW State Committee of the Royal Australian College of Surgeons, 9-11 September 1994.

- (23) Stewart JF, Bonaventura A, Ackland SP, Hamilton C, O'Brien P, Denham J: A phase II study of synchronous chemotherapy and radiotherapy for rectal cancer. Presented at European Society of Medical Oncology (ESMO) 1994.

- (24) Stewart JF Bonaventura A, Ackland SP, Kilmurray J, Hamilton C, O'Brien P, Denham J: Toxicity of synchronous chemotherapy and radiotherapy for rectal cancer. Presented at American Society of Clinical Oncology (ASCO) May 1995.

- (25) Leong D, Ackland SP, Bonaventura A, Stewart JF: Low risk febrile neutropenia in medical oncology. Presented at Clinical Oncological Society of Australia (COSA) December 1995.